Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s12883-017-0887-1
Published Online: 2017-06-05
Published Print: 2017-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Munsell, Michael
Frean, Molly
Menzin, Joseph
Phillips, Amy L.
Funding for this research was provided by:
EMD Serono
Pfizer